Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent storage stability. The pharmaceutical composition is provided to contain pemafibrate, a salt thereof or a solvate thereof, wherein a pH value of a solution produced by dissolving or dispersing the pharmaceutical composition in water is 7 or more.

A particulate composition suitable for oral consumption comprising: a carrier phase which is a free flowing particulate phase comprising a poor or bitter tasting agent and a first particulate agent; and a retained phase comprising a second particulate agent, wherein the second particulate agent is or comprises a flavour agent and/or a taste-masking agent, and wherein the residence time in the mouth of the retained phase (R.sub.90: retained) is greater than the residence time in the mouth of the carrier phase (R.sub.90: carrier).

The present invention relates to a directly compressible composition for the production of tablets which comprise fine-grained polyvinyl alcohols (PVAs) and fine-grained microcrystalline celluloses (MCCs) in a co-mixture. The present invention also relates to the use of this mixture and to a process for the preparation thereof.

Pharmaceutical composition particle capable of masking an unpalatable taste and improvement in dissolution properties, an orally disintegrating tablet containing the pharmaceutical composition particle, and a method for manufacturing a pharmaceutical composition particle. The pharmaceutical composition particle includes a core particle containing a drug and a water-soluble gelling swelling substance; and an outer layer which contains a water-insoluble substance and constitutes a coating provided on the outer side of the core particle. The method for manufacturing includes: pulverizing a water-soluble gelling swelling substance to have an average particle diameter of 15 m or less; a core particle manufacturing step of mixing the water-soluble gelling swelling substance pulverized and a drug to manufacture a core particle; and an outer layer formation step of coating the core particle with a water-insoluble substance on the outer side of the core particle.

An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.

The present invention relates to a novel combination drug in a solid oral dosage form comprising, as one of the three active ingredients, elsulfavirine sodium that may be suitable for medical use when treating viral infections including HIV and HBV.

An antiviral combination drug in a solid oral dosage form comprising, as one of the three active ingredients, a therapeutically effective amount of elsulfavirine sodium of formula 1a in a crystalline or polycrystalline form optionally in combination with auxiliary agents:

##STR00001##

The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.

Methods and compositions are provided which comprise effective amounts of an analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.

Pharmaceutical compositions for improving the solubility and dissolution of poorly soluble drugs which contain a therapeutic agent, a pharmaceutically acceptable polymer, and a spontaneously emulsifying component are described herein. These pharmaceutical compositions have been prepared by thermal processes to obtain a composition which shows improved properties including improved solubility of the therapeutic agent above the amount of therapeutic agent which should be soluble in either the spontaneously emulsifying component or the pharmaceutically acceptable polymer. Also provided herein are methods of preparing and use thereof.

An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.